Using the NIOSH Hazardous Drug List in a Pharmacy Assessment

The NIOSH hazardous drug list is a key reference, but the pharmacy must apply it to its own inventory and work processes. The current 2024 list replaced the 2016 list and received later updates. USP <800> calls for a facility-specific assessment of risk for dosage forms and activities; the list does not replace that assessment or the employer’s written procedures.

A list is a starting point

The National Institute for Occupational Safety and Health (NIOSH) identifies hazardous drugs using properties such as carcinogenicity, reproductive or developmental toxicity, organ toxicity at low doses, genotoxicity, or structure and toxicity similar to a known hazardous drug. Its list helps healthcare settings recognize drugs that may pose occupational risk. It is a powerful starting resource, not a substitute for assessing what a specific pharmacy receives, stores, prepares, administers, or disposes.

Use the current list

NIOSH published the 2024 hazardous drug list, which supersedes its 2016 list. The CDC/NIOSH page notes additions and removals and later updates for certain drugs. An employer should establish a process to review updates and compare the list with local inventory. A list downloaded years ago may omit newer drugs or retain entries that changed. Record which edition and date the assessment used.

The facility-specific assessment

USP <800> uses an assessment of risk to determine alternate containment strategies for certain dosage forms and activities, where the chapter permits them. This is a documented, drug- and task-specific review rather than a blanket “we do not compound that” statement. Relevant considerations include drug form, packaging, likelihood of exposure, manipulation, and whether the activity involves compounding or only handling a finished dosage form. The qualified person and safety team should follow current chapter text and applicable regulations.

Separate the drug list from the task assessment

A drug may be on the hazardous drug list, but the exposure pathway differs between counting intact tablets, opening a capsule, crushing a tablet, compounding a preparation, cleaning a spill, and disposing of waste. The workflow determines whether containment, PPE, or alternate controls are required. Do not treat a list entry as sufficient to decide that every handling task has identical risk, and do not use task-specific lower risk to erase the drug’s hazardous classification.

What records should show

A defensible program documents the list version, the pharmacy’s inventory cross-check, tasks evaluated, control decisions, training, and SOP updates. Keep the process current when the drug inventory, dosage forms, equipment, or work area changes. If the pharmacy begins handling a new product, route it through the assessment process before normal handling starts. Ensure staff can find the current list and know how to report an unrecognized hazardous item.

Example: a new product arrives

A new medication arrives in a sealed manufacturer bottle. The fact that it is an intact dosage form may change the exposure pathway, but it does not automatically remove the drug from the facility’s review. Staff verify the product against the current list and follow the approved handling and storage instructions. If the facility’s assessment does not cover this item or task, they ask the designated person before opening, manipulating, or placing it in ordinary stock.

A controlled way to update the inventory

Assign an owner to monitor the NIOSH page and any relevant USP updates. At a scheduled interval and when a new drug enters the formulary, compare the active inventory with current entries. Identify formulations and work practices, review whether the current controls remain adequate, update procedures and training, and document the approval. Ensure purchasing, receiving, and pharmacy systems can flag items that need special routing.

What NIOSH guidance does not do

The NIOSH list is not itself an individual patient safety warning and does not tell a technician how to prescribe or administer a drug. It is an occupational hazard reference. It also should not be treated as exhaustive without local review; CDC advises employers to consider drugs used in their own healthcare setting. Federal and state requirements, USP standards, and employer policies can affect what controls apply.

Exam-level reasoning

For a certification question, know that NIOSH identifies hazardous drugs and USP <800> addresses safe handling across the drug lifecycle. The organization maintains its own current list and risk assessment; staff follow resulting SOPs, containment controls, and PPE. When a new or uncertain medication appears, escalate rather than relying on memory or a stale printout.

PTCE takeaway

Use the current NIOSH list, match it to local inventory and tasks, document the facility-specific assessment, and update controls when products or processes change. The list informs the program; it does not replace USP <800>, the employer’s risk assessment, or approved SOPs.

Operational detail to remember

An assessment should be understandable to the people who must follow it. It should identify the product or drug group, the dosage form and task, the exposure concerns considered, the selected controls, and the person responsible for review. If the conclusion permits an alternate approach for a particular finished dosage form, it should say exactly which activity is covered and which activities are excluded. For example, handling a sealed tablet bottle and crushing a tablet are not the same task. Staff should be able to find the resulting SOP at the point of work and recognize when a situation falls outside its scope. If it does, pause and ask for a revised assessment rather than extending the exception by analogy.

Key points to carry into practice

• The NIOSH hazardous drug list is a key reference, but the pharmacy must apply it to its own inventory and work processes. The current 2024 list replaced the 2016 list and received later updates. USP <800> calls for a facility-specific assessment of risk for dosage forms and activities; the list does not replace that assessment or the employer’s written procedures.
• Check the current official standard, payer guidance, or facility SOP for the exact requirement.
• Pause and escalate uncertainty instead of extending a date, bypassing a claim edit, or improvising a safety procedure.